Welcome to our Evotec Blog.

Hope you will find our articles and resources relevant for your projects and interests.

Our experts are available for any additional information and to assist with your project challenges!

Just contact us.




Evotec achieves second milestone in diabetes alliance with Sanofi
Nerina Coppini, 25 June 2018

Companies are at the forefront of beta cell replacement therapeutic research for diabetes Evotec receives € 3 Million payment from Sanofi Milestone further demonstrates advancement of EVT Innovate initiative “TARGETBCD”

Evotec and Sanofi sign definitive agreement to combat infectious diseases
Nerina Coppini, 18 June 2018

Acceleration of research and development (“R&D”) of novel anti-infectives 100 employees will join Evotec Sanofi will license more than 10 infectious disease (“ID”) R&D assets Sanofi to provide significant support to Evotec including a one-time, upfront payment of € 60 M to support progression of a next generation anti-infectives portfolio

Evotec forms academic BRIDGE 'LAB591’ with Arix Bioscience and Fred Hutchinson Cancer Research Center
Nerina Coppini, 31 May 2018

Combination of one of the premier cancer research centers with a strong company builder and Evotec's drug discovery expertise to create and support new companies focused on therapeutic breakthroughs for patients in the areas of oncology and infectious diseases Expands Evotec's academic ‘BRIDGE’ initiative under EVT INNOVATE Initial term of...

Evotec and Celgene expand IPSC collaboration to include additional cell lines
Nerina Coppini, 29 May 2018

$ 6 M payment to access additional cell lines

Evotec and Celgene enter into strategic oncology partnership
Nerina Coppini, 21 May 2018

Leveraging Evotec's phenotypic screening capabilities and compound libraries with an initial focus on solid tumours Upfront payment of $ 65 M, significant milestone payments and tiered royalties per programme

Evotec reports First Quarter 2018 results and provides Corporate update
Nerina Coppini, 9 May 2018

55% increase in Group revenues Strong underlying operational performance with new business mix after Aptuit acquisition “3X30” outlook for 2018 confirmed Webcast and conference call today at 02.00 pm CEST

Evotec and Carna Biosciences collaborate on INDiGO platform
Nerina Coppini, 8 May 2018

Evotec leverages INDiGO platform to accelerate the development of Carna's programme CB-1763 through to IND filing IND-filing envisaged for first half of 2019 INDiGO, a key value-driving component of Evotec's EVT Execute business segment, accelerates early drug candidates into the clinic by reducing time from nomination to regulatory submission

Evotec expands CRISPR-based technology offering with licence from ERS genomics
Laura Catalina, 2 May 2018

Hamburg, Germany, 02 May 2018:Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that it has expanded its CRISPR service offering with the addition of a licence from ERS Genomics Limited. With this licence, Evotec gains access to the leading technology for gene editing, thereby complementing and expanding its...

Evotec and Bayer Advance Third Endometriosis Programme into Phase I Clinical Development
Nerina Coppini, 18 April 2018

Hamburg, Germany, 18 April 2018:Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its multi-target alliance with Bayer has advanced another promising small molecule into Phase I for the treatment of endometriosis, a painful, debilitating reproductive condition that affects approximately 176 million women...

Evotec forms collaboration with Petra Pharma on INDiGO platform
Nerina Coppini, 11 April 2018

Petra Pharma Corporation to harness Evotec's INDiGO platform to accelerate its lead programme (Petra-01 for oncology indications) through IND filing Evotec eligible to receive success-based milestones and research funding Evotec's INDiGO, a key value-driving component of its EVT Execute business segment, accelerates early drug candidates into...



Contact us


Business Development

T +44.(0)1235.86 15 61 T +1.732 329 2355 x3308